Login / Signup

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma.

Nobutaka NishimuraMakito MiyakeTakuto ShimizuAkira TachibanaNobumichi TanakaKiyohide Fujimoto
Published in: IJU case reports (2022)
Pembrolizumab rechallenge is not recommended in the current clinical setting of metastatic urothelial carcinoma, even for patients who showed complete response to the prior pembrolizumab.
Keyphrases
  • advanced non small cell lung cancer
  • squamous cell carcinoma
  • small cell lung cancer
  • epidermal growth factor receptor